how long to hold glp 1 prior to surgery American Society for Gastrointestinal Endoscopy position statement on periendoscopic management of patients on glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors ASA Advises No Longer Holding
Description
Clinical trial data from the STEP 1 extension study showed that after discontinuing semaglutide 2.4 mg, approximately two-thirds of weight loss was regained within one year
These trials have enriched the therapeutic landscape for T2D patients, offering a range of GLP-1 receptor agonists with varying cardiovascular profiles, thus allowing clinicians to personalize treatment for each patient
Those with a history of arrhythmias, uncontrolled hypertension, coronary artery disease, or previous cardiac events should approach this combination with extreme caution
Combined SGLT2i and GLP-1RA therapy resulted in a significantly lower risk of all-cause death, non-fatal myocardial infarction, and non-fatal stroke at 12 months than SGLT2i monotherapy (HR, 1.77
Benefits Our injectable treatments may accelerate your weight loss journey by potentially altering your metabolism and appetite
The minimal effective dose (MED) determined for both drugs was 0.5 nmol/kg/day
